|
| | 101ST GENERAL ASSEMBLY
State of Illinois
2019 and 2020 SB2340 Introduced 1/8/2020, by Sen. Laura Fine SYNOPSIS AS INTRODUCED: |
| |
Amends the Illinois Controlled Substances Act. Provides that a prescriber who is licensed to prescribe controlled substances shall, prior to issuing a prescription for an opioid that is a Schedule II controlled substance, discuss with a patient who is under 18 years of age and is an emancipated minor, or with the patient's parent or guardian if the patient is under 18 years of age and is not an emancipated minor, the risks of developing a physical or psychological dependence on the opioid and, if the prescriber deems it appropriate, any alternative treatments as may be available. Provides that a prescriber who engages in a discussion required under this provision shall include a note in the patient's medical record indicating that the discussion took place. Provides that the discussion required under this provision shall not be required prior to issuing a prescription to any patient who is currently receiving hospice care from a comprehensive hospice licensed under the Hospice Program Licensing Act. Effective immediately.
|
| |
| | A BILL FOR |
|
|
| | SB2340 | | LRB101 16214 RLC 65586 b |
|
|
1 | | AN ACT concerning criminal law.
|
2 | | Be it enacted by the People of the State of Illinois,
|
3 | | represented in the General Assembly:
|
4 | | Section 5. The Illinois Controlled Substances Act is |
5 | | amended by adding Section 315.6 as follows: |
6 | | (720 ILCS 570/315.6 new) |
7 | | Sec. 315.6. Prescriber to discuss risks of dependence on |
8 | | opioids with certain patients. |
9 | | (a) In this Section, "opioid" means a narcotic drug or |
10 | | substance that is a
Schedule II controlled substance under |
11 | | paragraph (1), (2), (3),
or (5) of subsection (b) or under |
12 | | subsection (c) of Section 206
of this Act. |
13 | | (b) A prescriber who is licensed to prescribe controlled |
14 | | substances shall, prior to issuing a prescription for an opioid |
15 | | that is a Schedule II controlled substance, discuss with a |
16 | | patient who is under 18 years of age and is an emancipated |
17 | | minor, or with the patient's parent or guardian if the patient |
18 | | is under 18 years of age and is not an emancipated minor, the |
19 | | risks of developing a physical or psychological dependence on |
20 | | the opioid and, if the prescriber deems it appropriate, any |
21 | | alternative treatments as may be available. |
22 | | (c) A prescriber who engages in a discussion required under |
23 | | subsection (b) shall include a note in the patient's medical |